Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?

Lena Weiss, Volker Heinemann,Laura E. Fischer, Frank Gieseler,Thomas Hoehler, Julia Mayerle,Detlef Quietzsch, Anke Reinacher-Schick,Michael Schenk, Gernot Seipelt,Jens T. Siveke, Michael Stahl,Ursula Vehling-Kaiser, Dirk T. Waldschmidt, Klara Dorman,Danmei Zhang, C. Benedikt Westphalen,Michael von Bergwelt-Baildon, Stefan Boeck,Michael Haas

Clinical and Translational Oncology（2023）

引用 0|浏览10

暂无评分

摘要

To analyze the 3-month life expectancy rate in pancreatic cancer (PC) patients treated within prospective trials from the German AIO study group. A pooled analysis was conducted for patients with advanced PC that were treated within five phase II/III studies conducted between 1997 and 2017 (Gem/Cis, Ro96, RC57, ACCEPT, RASH). The primary goal for the current report was to identify the actual 3-month survival rate, a standard inclusion criterion in oncology trials. Overall, 912 patients were included, 83

查看译文

关键词

Clinical trial,Inclusion criterion,Pancreatic cancer,Prognosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要